Literature DB >> 3137161

Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa.

S Vishwanath1, R Ramphal, C M Guay, D DesJardins, G B Pier.   

Abstract

Pseudomonas aeruginosa is a frequent respiratory tract colonizer in diseases in which mucociliary clearance is defective. The most striking of these is cystic fibrosis. The reasons for this organism's ability to colonize the respiratory tract and to persist there are not fully understood. Earlier studies showed that P. aeruginosa adheres preferentially to tracheobronchial mucin when compared with enterobacteria. We reasoned that if adherence to respiratory mucin protected P. aeruginosa from opsonophagocytic killing, then the ability of this organism to chronically colonize the respiratory tract could be partially explained. Using an opsonophagocytic killing assay with human polymorphonuclear leukocytes, we found that respiratory mucin protected six strains of P. aeruginosa from opsonophagocytic killing but did not protect poorly adhering strains of Escherichia coli, Staphylococcus aureus, or group B streptococci. Incubating P. aeruginosa with the mucin prior to addition to the opsonic assay inhibited phagocytic killing, whereas incubation of polymorphonuclear leukocytes with mucin did not, suggesting that inhibition was not due to an effect of mucin on leukocytes per se but was a consequence of bacterial adherence to mucin. Further studies indicated no decrease in the binding of either antibody or complement component C3 to the bacterial surface in the presence of mucin. This suggests that phagocytic inhibition may be due to a defect in uptake or destruction of mucin-coated bacteria by the leukocytes. Thus, the adherence of P. aeruginosa to respiratory mucin potentially contributes to its persistence in the respiratory tract by interfering with host immune responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137161      PMCID: PMC259552          DOI: 10.1128/iai.56.9.2218-2222.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

Authors:  M S Edwards; D L Kasper; H J Jennings; C J Baker; A Nicholson-Weller
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

2.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

3.  Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin.

Authors:  S Vishwanath; R Ramphal
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

4.  Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus.

Authors:  J C Lee; F Michon; N E Perez; C A Hopkins; G B Pier
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

5.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

7.  Relationship between the mouse colonizing ability of a human fecal Escherichia coli strain and its ability to bind a specific mouse colonic mucous gel protein.

Authors:  P S Cohen; R Rossoll; V J Cabelli; S L Yang; D C Laux
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  G Döring; H J Obernesser; K Botzenhart; B Flehmig; N Høiby; A Hofmann
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

9.  Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.

Authors:  A S Cross; W Zollinger; R Mandrell; P Gemski; J Sadoff
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  R B Fick; R S Baltimore; S U Squier; H Y Reynolds
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

View more
  13 in total

Review 1.  Recognition of mucin components by Pseudomonas aeruginosa.

Authors:  R Ramphal; S K Arora
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 2.  The role of bacterial adhesion in cystic fibrosis including the staphylococcal aspect.

Authors:  R Ramphal
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

3.  RahU: an inducible and functionally pleiotropic protein in Pseudomonas aeruginosa modulates innate immunity and inflammation in host cells.

Authors:  Jayasimha Rao; Michael R Elliott; Norbert Leitinger; Roderick V Jensen; Joanna B Goldberg; Ashok R Amin
Journal:  Cell Immunol       Date:  2011-05-24       Impact factor: 4.868

4.  Pathological and therapeutic significance of cellular invasion by Proteus mirabilis in an enterocystoplasty infection stone model.

Authors:  Rejiv B Mathoera; Dik J Kok; Cees M Verduin; Rien J M Nijman
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003.

Authors:  André M Cantin; Terry B White; Carroll E Cross; Henry Jay Forman; Ronald J Sokol; Drucy Borowitz
Journal:  Free Radic Biol Med       Date:  2006-09-29       Impact factor: 7.376

7.  Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.

Authors:  Reuben Ramphal; Viviane Balloy; Jeevan Jyot; Amrisha Verma; Mustapha Si-Tahar; Michel Chignard
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice.

Authors:  Shigeki Nakamura; Naoki Iwanaga; Masafumi Seki; Kenji Fukudome; Kazuhiro Oshima; Taiga Miyazaki; Koichi Izumikawa; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

10.  A murine model of chronic mucosal colonization by Pseudomonas aeruginosa.

Authors:  G B Pier; G Meluleni; E Neuger
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.